ZYME vs. VRNA

Last updated Jun 24, 2026

ZYME (Zymeworks Inc.) and VRNA (Verona Pharma plc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. At a 0.19 correlation, their price movements are largely independent.

Performance

ZYME vs. VRNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Zymeworks Inc. (ZYME) and Verona Pharma plc (VRNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

ZYME

• 1D: 2.67%
• 1M: -6.76%
• YTD: -9.30%
• 6M: -10.86%
• 1Y: 91.50%
• 3Y*: 43.33%
• 5Y*: -8.24%
• 10Y*: —

VRNA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

ZYME vs. VRNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ZYME Zymeworks Inc.	-9.30%	79.85%	40.90%	32.19%	-52.04%	-65.32%	3.96%	209.67%	93.33%	-43.75%
VRNA Verona Pharma plc	0.00%	130.21%	133.60%	-23.92%	288.84%	-4.00%	21.74%	-40.41%	-18.71%	-12.07%

Correlation

The correlation between ZYME and VRNA is 0.00, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.00
Correlation (3Y) Calculated over the trailing 3-year period	0.26
Correlation (5Y) Calculated over the trailing 5-year period	0.24
Correlation (All Time) Calculated using the full available price history since Apr 28, 2017	0.19

The correlation between ZYME and VRNA shifts across timeframes, from 0.00 (1 year) to 0.26 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap ZYME : $1.78B VRNA : $9.72B
EPS ZYME : -$583.41 VRNA : -$0.69
PS Ratio ZYME : 22.95 VRNA : 57.97
PB Ratio ZYME : 0.01 VRNA : 34.92
Total Revenue (TTM) ZYME : $78.86M VRNA : $167.65M
Gross Profit (TTM) ZYME : $77.16M VRNA : $159.52M
EBITDA (TTM) ZYME : -$47.18B VRNA : -$40.86M

Return for Risk

ZYME vs. VRNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ZYME

ZYME Risk / Return Rank: 87
ZYME Sharpe Ratio Rank: 86
ZYME Sortino Ratio Rank: 86
ZYME Omega Ratio Rank: 84
ZYME Calmar Ratio Rank: 90
ZYME Martin Ratio Rank: 87

VRNA

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ZYME vs. VRNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Zymeworks Inc. (ZYME) and Verona Pharma plc (VRNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	ZYME	VRNA	Difference
Sharpe ratio: Return per unit of total volatility	1.74	—	—
Sortino ratio: Return per unit of downside risk	2.69	—	—
Omega ratio: Gain probability vs. loss probability	1.33	—	—
Calmar ratio: Return relative to maximum drawdown	4.33	—	—
Martin ratio: Return relative to average drawdown	9.21	—	—

Drawdowns

Drawdown Indicators

	ZYME	VRNA	Difference
Max Drawdown Largest peak-to-trough decline	-91.81%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-21.25%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-45.75%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-87.53%	—	—
Current Drawdown Current decline from peak	-57.97%	—	—
Average Drawdown Average peak-to-trough decline	-52.54%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	9.97%	—	—

Volatility

Volatility by Period

	ZYME	VRNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.12%	—	—
Volatility (6M) Calculated over the trailing 6-month period	29.45%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	52.91%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	61.85%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	61.45%	—	—

Dividends

ZYME vs. VRNA - Dividend Comparison

Neither ZYME nor VRNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both ZYME and VRNA in my portfolio?

ZYME and VRNA have a correlation of 0.00, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.